311 related articles for article (PubMed ID: 33510766)
1. Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications.
Li Q; Zhang Z; Fan Y; Zhang Q
Front Genet; 2020; 11():562868. PubMed ID: 33510766
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics in renal cell cancer: mechanisms and clinical applications.
Joosten SC; Smits KM; Aarts MJ; Melotte V; Koch A; Tjan-Heijnen VC; van Engeland M
Nat Rev Urol; 2018 Jul; 15(7):430-451. PubMed ID: 29867106
[TBL] [Abstract][Full Text] [Related]
3. Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.
Kamli H; Li L; Gobe GC
Ochsner J; 2019; 19(2):138-151. PubMed ID: 31258426
[No Abstract] [Full Text] [Related]
4. Current Landscape of Epigenetics in Lung Cancer: Focus on the Mechanism and Application.
Shi YX; Sheng DQ; Cheng L; Song XY
J Oncol; 2019; 2019():8107318. PubMed ID: 31889956
[TBL] [Abstract][Full Text] [Related]
5. Emerging roles of interactions between ncRNAs and other epigenetic modifications in breast cancer.
Xie J; Gan L; Xue B; Wang X; Pei X
Front Oncol; 2023; 13():1264090. PubMed ID: 37901333
[TBL] [Abstract][Full Text] [Related]
6. Alterations of epigenetics and microRNA in hepatocellular carcinoma.
Saito Y; Hibino S; Saito H
Hepatol Res; 2014 Jan; 44(1):31-42. PubMed ID: 23617364
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.
Castilho RM; Squarize CH; Almeida LO
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28704968
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs as predictive biomarkers of response to tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma.
Kovacova J; Poprach A; Buchler T; Cho WC; Slaby O
Clin Chem Lab Med; 2018 Aug; 56(9):1426-1431. PubMed ID: 29451857
[TBL] [Abstract][Full Text] [Related]
9. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
10. Emerging tyrosine kinase inhibitors for the treatment of renal cancer.
Iacovelli R; Albiges L; Escudier B
Expert Opin Emerg Drugs; 2015 Sep; 20(3):379-92. PubMed ID: 25982181
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer: epigenetics, drug resistance, and progression.
Xie W; Sun H; Li X; Lin F; Wang Z; Wang X
Cancer Cell Int; 2021 Aug; 21(1):434. PubMed ID: 34404407
[TBL] [Abstract][Full Text] [Related]
12. The role of epigenetics in kidney malignancies.
la Rosa AH; Acker M; Swain S; Manoharan M
Cent European J Urol; 2015; 68(2):157-64. PubMed ID: 26251734
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics.
Li Y; Li Z; Zhu WG
Curr Med Chem; 2019; 26(8):1328-1350. PubMed ID: 28933282
[TBL] [Abstract][Full Text] [Related]
14. SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway.
Li XL; Chen XQ; Zhang MN; Chen N; Nie L; Xu M; Gong J; Shen PF; Su ZZ; Weng X; Tan JY; Zhao T; Zeng H; Zhou Q
Int J Clin Exp Pathol; 2015; 8(4):3871-81. PubMed ID: 26097571
[TBL] [Abstract][Full Text] [Related]
15. miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance.
Ricciuti B; Mecca C; Cenci M; Leonardi GC; Perrone L; Mencaroni C; Crinò L; Grignani F; Baglivo S; Chiari R; Sidoni A; Paglialunga L; Currà MF; Murano E; Minotti V; Metro G
Ecancermedicalscience; 2015; 9():569. PubMed ID: 26435742
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modulation of metabolism in glioblastoma.
Dong Z; Cui H
Semin Cancer Biol; 2019 Aug; 57():45-51. PubMed ID: 30205139
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation in human melanoma: past and future.
Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
[TBL] [Abstract][Full Text] [Related]
19. The Emerging Role of Histone Demethylases in Renal Cell Carcinoma.
Guo X; Zhang Q
J Kidney Cancer VHL; 2017; 4(2):1-5. PubMed ID: 28725537
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
